(Q37738541)

22 August 2017

1 reference

title

Targeting chronic myeloid leukemia stem cells (English)

1 reference

22 August 2017

chronic myeloid leukemia

0 references

1 reference

G Vignir Helgason

1

0 references

Tessa Holyoake

object named as

Tessa L Holyoake

series ordinal

3

0 references

author name string

Graham A R Young

series ordinal

2

1 reference

22 August 2017

1 April 2010

1 reference

Current hematologic malignancy reports

22 August 2017

1 reference

22 August 2017

5

1 reference

22 August 2017

2

1 reference

22 August 2017

81-87

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-010-0043-0

22 August 2017

0 references

cites work

The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-010-0043-0

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

21 January 2018

1 reference

12 December 2020

BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress

1 reference

12 December 2020

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

1 reference

12 December 2020

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

12 December 2020

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

12 December 2020

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

1 reference

12 December 2020

IFNalpha activates dormant haematopoietic stem cells in vivo.

1 reference

12 December 2020

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

1 reference

12 December 2020

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

1 reference

12 December 2020

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.

1 reference

12 December 2020

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

12 December 2020

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

12 December 2020

FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis

1 reference

12 December 2020

IFN-alpha wakes up sleeping hematopoietic stem cells.

1 reference

12 December 2020

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

1 reference

12 December 2020

mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein

1 reference

12 December 2020

FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress

1 reference

12 December 2020

Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor

1 reference

12 December 2020

Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.

1 reference

12 December 2020

PML targeting eradicates quiescent leukaemia-initiating cells

1 reference

12 December 2020

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

1 reference

12 December 2020

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

1 reference

12 December 2020

Autophagy: basic principles and relevance to disease

1 reference

12 December 2020

Novel agents in CML therapy: tyrosine kinase inhibitors and beyond

1 reference

12 December 2020

Targeted therapies and autophagy: new insights from chronic myeloid leukemia

1 reference

12 December 2020

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

1 reference

12 December 2020

Chromosome studies on normal and leukemic human leukocytes

1 reference

12 December 2020

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

1 reference

12 December 2020

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

1 reference

12 December 2020

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

1 reference

12 December 2020

Lysosomes and autophagy in cell death control

1 reference

12 December 2020

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

1 reference

12 December 2020

Evolving concepts on the microenvironmental niche for hematopoietic stem cells

1 reference

12 December 2020

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

1 reference

12 December 2020

Homoharringtonine for the treatment of chronic myelogenous leukemia

1 reference

12 December 2020

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

1 reference

12 December 2020

Inhibitors of ABL and the ABL-T315I mutation

1 reference

12 December 2020

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

1 reference

12 December 2020

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

1 reference

12 December 2020

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

1 reference

12 December 2020

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

12 December 2020

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

1 reference

12 December 2020

Research on resistance to cancer drug Gleevec

1 reference

12 December 2020

FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system

1 reference

12 December 2020

Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors

1 reference

12 December 2020

JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.

1 reference

12 December 2020

Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors

1 reference

12 December 2020

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

12 December 2020

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

12 December 2020

Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells

1 reference

12 December 2020

Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.

1 reference

12 December 2020

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

12 December 2020

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

12 December 2020

10.1007/S11899-010-0043-0

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20425400